Genetics may shape GLP‑1 response
A new study from 23andMe suggests genetic variants can partly explain why GLP‑1 weight‑loss drugs help some people much more than others and why side effects vary — so your DNA might influence how you respond to drugs like Ozempic ( ). That finding lands as Eli Lilly’s oral GLP‑1 weight‑loss pill became available in the U.S. on April 9, potentially widening access beyond injections — but experts warn patients can still face significant extra costs treating side effects and managing care ( ). Retail ripple effects are already visible — apparel retailers report shifts in size demand as millions use GLP‑1s, so weight-loss meds are now reshaping wardrobes, budgets, and training choices as much as pounds (cnbc.com).
The newest clue in the weight-loss drug boom is not a new shot or a new pill. It is a DNA result: a Nature study from the 23andMe Research Institute found that common genetic variants were linked to both how much weight people lost on these drugs and how likely they were to get nausea or vomiting. (nature.com) These medicines copy gut hormones that tell the brain “you’ve had enough” and tell the stomach to empty more slowly, which is why people often feel full sooner and eat less. Drugs in this group include semaglutide, sold as Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro. (nature.com) The puzzle is that two people can take the same drug and get very different results. One person may lose a large share of body weight, while another loses much less or stops because the stomach side effects are too hard to tolerate. (scientificamerican.com) To test whether genes help explain that gap, 23andMe researchers looked at data from 27,885 people who reported using one of these medicines. They searched the genome the way you would scan a city map for repeated traffic jams, looking for spots that kept showing up in people with stronger weight loss or worse side effects. (nature.com) The strongest weight-loss signal showed up near a gene called GLP1R, which is the instruction book for the receptor these drugs are designed to hit. If the drug is a key, that receptor is the lock, so small inherited differences in the lock can change how strongly the medicine works. (nature.com, 23andme.com) A second signal showed up near a gene called GIPR, another hormone receptor involved in appetite and metabolism. In the study, variation near GIPR was tied to nausea or vomiting, and that link was limited to people using tirzepatide, which targets both receptors rather than one. (nature.com) The important catch is scale. Scientists quoted by Scientific American said the gene effects were real but modest, which means DNA is one factor among many others, including dose, diet, exercise, diabetes status, sex, and whether a patient stays on the drug long enough to benefit. (scientificamerican.com) This landed just as Eli Lilly widened the market on April 9 by launching its once-daily oral weight-loss drug Foundayo in the United States through LillyDirect, telehealth providers, and pharmacies. UPI reported that Lilly said 55% of patients in the 36 milligram group lost at least 10% of body weight in trials. (upi.com, fiercehealthcare.com) A pill matters because injections are a hurdle for some patients, but easier access does not erase the rest of the bill. Pharm Exec reported this week that patients can still face extra spending for side-effect treatment, follow-up care, nutrition support, and other services that sit outside the sticker price of the drug itself. (pharmexec.com) The effects are now showing up far from the clinic. CNBC reported on April 9 that Bernstein estimates GLP-1 adoption could add as much as $13 billion a year to apparel spending, with retailers like T.J. Maxx, Walmart, Target, Stitch Fix, and Rent the Runway positioned to benefit as customers buy new sizes. (cnbc.com) So the next phase of this market is getting more personal in two directions at once. The drugs are spreading to more people through pills, while the science is moving toward a future where doctors may use a patient’s genes to estimate not just whether a weight-loss drug will work, but how rough the ride might be. (nature.com, 23andme.com, upi.com)
